The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.
Abstract
Fifteen patients (11 males, four females; median age 57) manifested a disease characterized by (1) the histopathologic features of Castleman's disease, plasma cell type, in lymph node biopsies; (2) predominantly lymphadenopathic disease, involving multiple, preferentially peripheral nodal groups; (3) varied manifestations of multisystemic involvement (such as constitutional symptoms; splenomegaly and hypergammaglobulinemia; elevated ESR, anemia, and thrombocytopenia; hepatomegaly and altered liver function tests (LFTs); signs of renal disease); and (4) idiopathic nature. Two main patterns of evolution were recognized: persistent, with sustained clinical manifestations, and episodic, with recurrent exacerbations and remissions. Seventy-three percent of patients had infectious complications, and 27% developed malignancies. Complete remissions were obtained occasionally with antineoplastic agents and with splenectomy but not with glucocorticosteroids alone. The median survival time is 30 months; 60% of patients have died. Median follow-up in the six surviving patients is 97+ months. A review of 50 cases in the literature revealed similar clinical and laboratory features. Despite some similarities with autoimmune diseases, the main features of this process seem to best fit a hyperplastic-dysplastic lymphoid disorder in a setting of immunoregulatory deficit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Localized mediastinal lymph-node hyperplasia resembling thymoma
Castleman, B., Iverson, L., & Menendez, V. P. (1956) · Cancer · doi:10.1002/1097-0142(195607/08)9:4<822::aid-cncr2820090430>3.0.co;2-4 · Cited by 1,621
Keller, A. R., Hochholzer, L., & Castleman, B. (1972) · Cancer · doi:10.1002/1097-0142(197203)29:3<670::aid-cncr2820290321>3.0.co;2-# · Cited by 1,355
Age Influence on the Immune System
Makinodan, T., & Kay, M. M. B. (1980) · Advances in Immunology · doi:10.1016/s0065-2776(08)60047-4 · Cited by 699
BARDWICK, P. A., ZVAIFLER, N. J., GILL, G. N., NEWMAN, D., GREENWAY, G. D., & RESNICK, D. L. (1980) · Medicine · doi:10.1097/00005792-198007000-00006 · Cited by 699
Angio-immunoblastic lymphadenopathy
Frizzera, G., Moran, E. M., & Rappaport, H. (1975) · The American Journal of Medicine · doi:10.1016/0002-9343(75)90466-0 · Cited by 403
Self-citationMulticentric angiofollicular lymph node hyperplasia: A clinicopathologic study of 16 cases
Weisenburger, D. D., Nathwani, B. N., Winberg, C. D., & Rappaport, H. (1985) · Human Pathology · doi:10.1016/s0046-8177(85)80065-4 · Cited by 376
Multicentric Giant Lymph Node Hyperplasia
Gaba, A. R., Stein, R. S., Sweet, D. L., & Variakojis, D. (1978) · American Journal of Clinical Pathology · doi:10.1093/ajcp/69.1.86 · Cited by 359
JAFFE, H. W., CHOI, K., THOMAS, P. A., HAVERKOS, H. W., AUERBACH, D. M., GUINAN, M. E., ROGERS, M. F., SPIRA, T. J., DARROW, W. W., KRAMER, M. A., et al. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-99-2-145 · Cited by 356
Castleman's disease: More questions than answers
Frizzera, G. (1985) · Human Pathology · doi:10.1016/s0046-8177(85)80002-2 · Cited by 173
Self-citationKlepp, O., Dahl, O., & Stenwig, J. T. (1978) · Cancer · Cited by 156
Cited by
Soulier, J., Grollet, L., Oksenhendler, E., Cacoub, P., Cazals-Hatem, D., Babinet, P., d'Agay, M., Clauvel, J., Raphael, M., Degos, L., et al. (1995) · Blood · doi:10.1182/blood.v86.4.1276.bloodjournal8641276 · Cited by 2,157
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease
Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T. (1989) · Blood · doi:10.1182/blood.v74.4.1360.1360 · Cited by 928
Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease
Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4602 · Cited by 754
Dispenzieri, A., & Fajgenbaum, D. C. (2020) · Blood · doi:10.1182/blood.2019000931 · Cited by 487
Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy
Nishimoto, N., Sasai, M., Shima, Y., Nakagawa, M., Matsumoto, T., Shirai, T., Kishimoto, T., & Yoshizaki, K. (2000) · Blood · doi:10.1182/blood.v95.1.56 · Cited by 441
van Rhee, F., Voorhees, P., Dispenzieri, A., Fosså, A., Srkalovic, G., Ide, M., Munshi, N., Schey, S., Streetly, M., Pierson, S. K., et al. (2018) · Blood · doi:10.1182/blood-2018-07-862334 · Cited by 426
The Clinical Behavior of Localized and Multicentric Castleman Disease
Herrada, J., Cabanillas, F., Rice, L., Manning, J., & Pugh, W. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-8-199804150-00010 · Cited by 413
Bowne, W. B., Lewis, J. J., Filippa, D. A., Niesvizky, R., Brooks, A. D., Burt, M. E., & Brennan, M. F. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990201)85:3<706::aid-cncr21>3.0.co;2-7 · Cited by 411
Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice
Screpanti, I., Romani, L., Musiani, P., Modesti, A., Fattori, E., Lazzaro, D., Sellitto, C., Scarpa, S., Bellavia, D., & Lattanzio, G. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07185.x · Cited by 407
Casper, C. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05311.x · Cited by 354
Kaposi's sarcoma-associated herpesvirus encodes a functional Bcl-2 homologue
Sarid, R., Sato, T., Bohenzky, R. A., Russo, J. J., & Chang, Y. (1997) · Nature Medicine · doi:10.1038/nm0397-293 · Cited by 352
Fajgenbaum, D. C., van Rhee, F., & Nabel, C. S. (2014) · Blood · doi:10.1182/blood-2013-12-545087 · Cited by 331
Castleman Disease: An Update on Classification and the Spectrum of Associated Lesions
Cronin, D. M. P., & Warnke, R. A. (2009) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181a9d4d3 · Cited by 311
Iwaki, N., Fajgenbaum, D. C., Nabel, C. S., Gion, Y., Kondo, E., Kawano, M., Masunari, T., Yoshida, I., Moro, H., Nikkuni, K., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24242 · Cited by 296
“Multicentric Castleman disease (MCD) is a rare disorder often characterized by episodes of systemic inflammation, reactive proliferation of morphologically benign lymphocytes, multicentric lymphadenopathy, polyclonal gammaglobulinemia, microcytic anemia, hypoalbuminemia, and elevated serum inflammatory proteins, such…”
BackgroundSato, Y., Kojima, M., Takata, K., Morito, T., Asaoku, H., Takeuchi, T., Mizobuchi, K., Fujihara, M., Kuraoka, K., Nakai, T., et al. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.17 · Cited by 280
Dysregulated interleukin 6 expression produces a syndrome resembling Castleman’s disease in mice
Brandt, S. J., Bodine, D. M., Dunbar, C. E., & Nienhuis, A. W. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114749 · Cited by 248
Inhibition of IL-6 for the treatment of inflammatory diseases
NISHIMOTO, N. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.03.005 · Cited by 200
Polizzotto, M. N., Uldrick, T. S., Wang, V., Aleman, K., Wyvill, K. M., Marshall, V., Pittaluga, S., O’Mahony, D., Whitby, D., Tosato, G., et al. (2013) · Blood · doi:10.1182/blood-2013-08-519959 · Cited by 158
“Symptom severity‡ (median, Range) 2 (1-3) 2 (1-3) 2 (1-2) 2 (2-2) NA”
Background
Metadata
- Authors
- Frizzera, G., Peterson, B. A., Bayrd, E. D., & Goldman, A.
- Venue
- Journal of Clinical Oncology
- Published
- 1985-09
- Volume
- 3
- Issue
- 9
- Pages
- 1202-1216
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1958017333
- Cited by
- 380
- References
- 12
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.